Target price | €186.27 |
Course | €150.00 |
Price potential | 24.18% |
Number of estimates | 15 |
15 Analysts have issued a price target Merck 2025 . The average Merck target price is €186.27. This is 24.18% higher than the current share price. The highest price target is €210.00 40.00% , the lowest is €160.00 6.67% . | |
A rating was issued by 17 analysts: 15 Analysts recommend Merck to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst estimates: Analysts believe that the Merck share has an average upside potential 2025 of 24.18% . Most analysts recommend the Merck share at Purchase. |
13 Analysts have issued a sales forecast Merck 2024 . The average Merck sales estimate is €21.3b . This is 2.31% higher than the turnover of the last 12 months(TTM). The highest sales forecast is €21.5b 3.06% , the lowest is €21.1b 1.12% .
This results in the following potential growth figures:
2023 | €21.0b | 5.57% |
---|---|---|
2024 | €21.3b | 1.47% |
2025 | €22.7b | 6.35% |
2026 | €23.9b | 5.70% |
2027 | €25.1b | 5.03% |
2028 | €26.5b | 5.50% |
13 Analysts have issued an Merck EBITDA forecast 2024. The average Merck EBITDA estimate is €5.9b . This is 1.30% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.2b 3.94% , the lowest is €5.6b 6.20% .
This results in the following potential growth figures and future EBITDA margins:
2023 | €5.8b | 15.15% |
---|---|---|
2024 | €5.9b | 1.73% |
2025 | €6.7b | 12.24% |
2026 | €7.3b | 9.17% |
2027 | €7.6b | 4.12% |
2028 | €8.0b | 5.46% |
2023 | 27.75% | 10.14% |
---|---|---|
2024 | 27.82% | 0.26% |
2025 | 29.36% | 5.54% |
2026 | 30.33% | 3.30% |
2027 | 30.07% | 0.86% |
2028 | 30.05% | 0.07% |
12 Merck Analysts have issued a net profit forecast 2024. The average Merck net profit estimate is €3.0b . This is 9.65% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.2b 18.70% , the lowest is €2.8b 2.98% .
This results in the following potential growth figures and future net margins:
2023 | €2.8b | 15.03% |
---|---|---|
2024 | €3.0b | 5.60% |
2025 | €3.6b | 18.95% |
2026 | €4.0b | 11.86% |
2027 | €4.3b | 8.12% |
2028 | €4.7b | 8.98% |
2023 | 13.46% | 10.02% |
---|---|---|
2024 | 14.01% | 4.07% |
2025 | 15.67% | 11.85% |
2026 | 16.59% | 5.87% |
2027 | 17.07% | 2.89% |
2028 | 17.64% | 3.34% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck <a href=/blog/eps>EPS is €6.86 . This is 9.58% higher than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is €7.43 18.69% , the lowest is €6.45 3.04% .
This results in the following potential growth figures and future valuations:
2023 | €6.50 | 15.03% |
---|---|---|
2024 | €6.86 | 5.54% |
2025 | €8.17 | 19.10% |
2026 | €9.13 | 11.75% |
2027 | €9.88 | 8.21% |
2028 | €10.76 | 8.91% |
Current | 23.95 | 11.34% |
---|---|---|
2024 | 21.85 | 8.77% |
2025 | 18.37 | 15.93% |
2026 | 16.42 | 10.62% |
2027 | 15.19 | 7.49% |
2028 | 13.94 | 8.23% |
Based on analysts' sales estimates for 2024, the Merck share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of 3.43 and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of 3.06 .
This results in the following potential growth figures and future valuations:
Current | 3.51 | 4.46% |
---|---|---|
2024 | 3.43 | 2.32% |
2025 | 3.22 | 5.97% |
2026 | 3.05 | 5.39% |
2027 | 2.90 | 4.78% |
2028 | 2.75 | 5.22% |
Current | 3.13 | 6.14% |
---|---|---|
2024 | 3.06 | 2.26% |
2025 | 2.88 | 5.97% |
2026 | 2.72 | 5.39% |
2027 | 2.59 | 4.79% |
2028 | 2.46 | 5.22% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.